Integrated Advisors Network LLC Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Integrated Advisors Network LLC increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 17.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,603 shares of the company’s stock after buying an additional 3,015 shares during the quarter. Integrated Advisors Network LLC’s holdings in Recursion Pharmaceuticals were worth $109,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of RXRX. Ensign Peak Advisors Inc boosted its holdings in Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock valued at $2,774,000 after purchasing an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after purchasing an additional 1,875 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after purchasing an additional 2,026 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Recursion Pharmaceuticals by 28.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock valued at $69,000 after purchasing an additional 2,235 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Down 4.8%

Shares of Recursion Pharmaceuticals stock opened at $4.92 on Monday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business’s 50 day simple moving average is $4.89 and its 200-day simple moving average is $6.32. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -3.22 and a beta of 0.84. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.39) earnings per share. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RXRX. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.